Aging Clinical and Experimental Research

, Volume 26, Issue 2, pp 193–199

Serum cystatin C and indices of lung function in elderly Chinese men with chronic obstructive pulmonary disease

  • Meng Zhang
  • Shu-Hong Fu
  • Hua Cui
  • Bing-Po Zhu
  • Lin Liu
  • De-Long Wang
Original Article
  • 104 Downloads

Abstract

Objective

The aim of this cross-sectional case–control study was to determine the relationship between serum cystatin C (sCysC) levels and lung function in elderly male patients with chronic obstructive pulmonary disease (COPD).

Methods

This study included 251 Chinese men (age ≥ 65 years) who were divided into COPD (n = 129) and non-COPD (n = 122) groups. Participants underwent lung function and laboratory testing, including measurement of sCysC levels. Relationships between sCysC concentration and indices of lung function were assessed by multiple regression analysis.

Results

Participants in the COPD group displayed higher sCysC concentrations (P = 0.041) and lower lung function (P < 0.001) compared to participants in the non-COPD group. Multiple linear regression analyses revealed that the reciprocal of the sCysC concentration (1/sCysC) was positively associated with the predicted forced expiratory volume in 1 s in all subjects (β = 0.156, P = 0.009). The findings indicate that high sCysC levels were directly associated with decreased lung function in elderly Chinese men with COPD.

Conclusions

High sCysC concentration may be a potential indicator of impaired lung function, and its application may improve the diagnosis and assessment of COPD severity in elderly male patients.

Keywords

Cystatin C Chronic obstructive pulmonary disease Lung function Elderly patient 

Supplementary material

40520_2013_150_MOESM1_ESM.doc (64 kb)
Supplementary material 1 (DOC 63 kb)

References

  1. 1.
    Global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung Disease (GOLD) 2011 http://www.goldcopd.org/. Accessed December 2011
  2. 2.
    Buist AS, Vollmer WM, McBurnie MA (2008) Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. Int J Tuberc Lung Dis 12(7):703–708PubMedGoogle Scholar
  3. 3.
    Fletcher C, Peto R (1977) The natural history of chronic airflow obstruction. Br Med J 1(6077):1645–1648PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, Chen B, Wang C, Ni D, Zhou Y, Liu S, Wang X, Wang D, Lu J, Zheng J, Ran P (2007) Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med 176(8):753–760PubMedCrossRefGoogle Scholar
  5. 5.
    Akgun KM, Crothers K, Pisani M (2012) Epidemiology and management of common pulmonary diseases in older persons. J Gerontol A Biol Sci Med Sci 67(3):276–291PubMedCrossRefGoogle Scholar
  6. 6.
    China’s major health challenge: control of chronic diseases (2011). Lancet 378(9790):457Google Scholar
  7. 7.
    Fang X, Wang X, Bai C (2011) COPD in China: the burden and importance of proper management. Chest 139(4):920–929PubMedCrossRefGoogle Scholar
  8. 8.
    Owen CA (2008) Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 3(2):253–268PubMedCentralPubMedGoogle Scholar
  9. 9.
    Gottlieb DJ, Stone PJ, Sparrow D, Gale ME, Weiss ST, Snider GL, O’Connor GT (1996) Urinary desmosine excretion in smokers with and without rapid decline of lung function: the normative aging study. Am J Respir Crit Care Med 154(5):1290–1295PubMedCrossRefGoogle Scholar
  10. 10.
    Newman DJ (2002) Cystatin C. Ann Clin Biochem 39(Pt 2):89–104PubMedCrossRefGoogle Scholar
  11. 11.
    Rokadia HK, Agarwal S (2012) Serum cystatin C and emphysema: results from the National Health and Nutrition Examination Survey (NHANES). Lung 190(3):283–290PubMedCrossRefGoogle Scholar
  12. 12.
    Zheng T, Zhu Z, Wang Z, Homer RJ, Ma B, Riese RJ Jr, Chapman HA Jr, Shapiro SD, Elias JA (2000) Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest 106(9):1081–1093PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    van Durme YM, Verhamme KM, Stijnen T, van Rooij FJ, Van Pottelberge GR, Hofman A, Joos GF, Stricker BH, Brusselle GG (2009) Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. Chest 135(2):368–377PubMedCrossRefGoogle Scholar
  14. 14.
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461–470PubMedCrossRefGoogle Scholar
  15. 15.
    Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G (2005) Standardisation of the measurement of lung volumes. Eur Respir J 26(3):511–522PubMedCrossRefGoogle Scholar
  16. 16.
    Mussap M, Plebani M (2004) Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 41(5–6):467–550PubMedCrossRefGoogle Scholar
  17. 17.
    Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C (2005) Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352(20):2049–2060PubMedCrossRefGoogle Scholar
  18. 18.
    Ferraro S, Marano G, Biganzoli EM, Boracchi P, Bongo AS (2011) Prognostic value of cystatin C in acute coronary syndromes: enhancer of atherosclerosis and promising therapeutic target. Clin Chem Lab Med 49(9):1397–1404PubMedCrossRefGoogle Scholar
  19. 19.
    Lee YT, Chen SC, Shyu LY, Lee MC, Wu TC, Tsao SM, Yang SF (2012) Significant elevation of plasma cathepsin B and cystatin C in patients with community-acquired pneumonia. Clin Chim Acta 413(5–6):630–635PubMedCrossRefGoogle Scholar
  20. 20.
    Shastri S, Katz R, Shlipak MG, Kestenbaum B, Peralta CA, Kramer H, Jacobs DR Jr, de Boer IH, Cushman M, Siscovick D, Sarnak MJ (2011) Cystatin C and albuminuria as risk factors for development of CKD stage 3: the multi-ethnic study of atherosclerosis (MESA). Am J Kidney Dis 57(6):832–840PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Buttle DJ, Burnett D, Abrahamson M (1990) Levels of neutrophil elastase and cathepsin B activities, and cystatins in human sputum: relationship to inflammation. Scand J Clin Lab Invest 50(5):509–516PubMedCrossRefGoogle Scholar
  22. 22.
    Cimerman N, Brguljan PM, Krasovec M, Suskovic S, Kos J (2000) Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. Clin Chim Acta 300(1–2):83–95PubMedCrossRefGoogle Scholar
  23. 23.
    Kos J, Werle B, Lah T, Brunner N (2000) Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int J Biol Markers 15(1):84–89PubMedGoogle Scholar
  24. 24.
    Werle B, Sauckel K, Nathanson CM, Bjarnadottir M, Spiess E, Ebert W, Abrahamson M (2003) Cystatins C, E/M and F in human pleural fluids of patients with neoplastic and inflammatory lung disorders. Biol Chem 384(2):281–287PubMedCrossRefGoogle Scholar
  25. 25.
    Curkendall SM, Lanes S, de Luise C, Stang MR, Jones JK, She D, Goehring E Jr (2006) Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur J Epidemiol 21(11):803–813PubMedCrossRefGoogle Scholar
  26. 26.
    Deo R, Fyr CL, Fried LF, Newman AB, Harris TB, Angleman S, Green C, Kritchevsky SB, Chertow GM, Cummings SR, Shlipak MG, Health ABCs (2008) Kidney dysfunction and fatal cardiovascular disease–an association independent of atherosclerotic events: results from the health, aging, and body composition (Health ABC) study. Am Heart J 155 (1):62–68Google Scholar
  27. 27.
    Incalzi RA, Corsonello A, Pedone C, Battaglia S, Paglino G, Bellia V, Extrapulmonary consequences of CitESI (2010) Chronic renal failure: a neglected comorbidity of COPD. Chest 137(4):831–837PubMedCrossRefGoogle Scholar
  28. 28.
    Dharnidharka VR, Kwon C, Stevens G (2002) Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40(2):221–226PubMedCrossRefGoogle Scholar
  29. 29.
    Shlipak MG, Praught ML, Sarnak MJ (2006) Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens 15(3):270–275PubMedCrossRefGoogle Scholar
  30. 30.
    Ischaki E, Papatheodorou G, Gaki E, Papa I, Koulouris N, Loukides S (2007) Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity. Chest 132(1):164–169PubMedCrossRefGoogle Scholar
  31. 31.
    Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, Pardini E, Miccoli R, Del Prato S, Penno G (2007) Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem 53(3):480–488PubMedCrossRefGoogle Scholar
  32. 32.
    Jarad N (2011) Chronic obstructive pulmonary disease (COPD) and old age? Chron Respir Dis 8(2):143–151PubMedGoogle Scholar
  33. 33.
    Kottgen A, Selvin E, Stevens LA, Levey AS, Van Lente F, Coresh J (2008) Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 51(3):385–394PubMedCrossRefGoogle Scholar
  34. 34.
    Cardiovascular Health Study Research G, Newman AB, Arnold AM, Naydeck BL, Fried LP, Burke GL, Enright P, Gottdiener J, Hirsch C, O’Leary D, Tracy R (2003) Successful aging: effect of subclinical cardiovascular disease. Arch Intern Med 163(19):2315–2322PubMedCrossRefGoogle Scholar
  35. 35.
    Sarnak MJ, Katz R, Fried LF, Siscovick D, Kestenbaum B, Seliger S, Rifkin D, Tracy R, Newman AB, Shlipak MG, Cardiovascular Health S (2008) Cystatin C and aging success. Arch Intern Med 168 (2):147–153Google Scholar
  36. 36.
    Grubb A, Bjork J, Nyman U, Pollak J, Bengzon J, Ostner G, Lindstrom V (2011) Cystatin C, a marker for successful aging and glomerular filtration rate, is not influenced by inflammation. Scand J Clin Lab Invest 71(2):145–149PubMedCentralPubMedGoogle Scholar
  37. 37.
    Larsson A, Helmersson J, Hansson LO, Basu S (2008) Serum cystatin C is associated with other cardiovascular risk markers and cardiovascular disease in elderly men. Int J Cardiol 125(2):263–264PubMedCrossRefGoogle Scholar
  38. 38.
    Bhatt NY, Wood KL (2008) What defines abnormal lung function in older adults with chronic obstructive pulmonary disease? Drugs Aging 25(9):717–728PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Meng Zhang
    • 1
  • Shu-Hong Fu
    • 2
  • Hua Cui
    • 3
  • Bing-Po Zhu
    • 4
  • Lin Liu
    • 2
  • De-Long Wang
    • 2
  1. 1.Cardiology DivisionFu Wai Hospital and Cardiovascular Institute, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical CollegeBeijingChina
  2. 2.Clinical Department of GeriatricsChinese PLA General HospitalBeijingChina
  3. 3.Second Geriatric Cardiology Division, Department of GeriatricsChinese PLA General HospitalBeijingChina
  4. 4.First Geriatric Cardiology DivisionChinese PLA General HospitalBeijingChina

Personalised recommendations